Evidence that soyasaponin Bb retards disease progression in a murine model of polycystic kidney disease  by Philbrick, Diana J. et al.
Kidney International, Vol. 63 (2003), pp. 1230–1239
Evidence that soyasaponin Bb retards disease progression in a
murine model of polycystic kidney disease
DIANA J. PHILBRICK, DOMINIQUE P. BUREAU, F. WILLIAM COLLINS,1 and BRUCE J. HOLUB
Departments of Human Biology and Nutritional Sciences and Animal and Poultry Science, University of Guelph, Guelph,
Ontario, Canada; and the Eastern Cereal and Oilseed Research Centre (ECORC), Ottawa, Ontario, Canada
Evidence that soyasaponin Bb retards disease progression in a accepted animal model of PKD [1]. We have reported
murine model of polycystic kidney disease. that changes associated with disease progression, includ-
Background. We reported a lessened cyst growth in the pcy ing total kidney weight, kidney weight relative to bodymouse model of polycystic kidney disease (PKD) when mice
weight, mean cyst volume, and organ water content, werewere fed a soy protein isolate (SPI)–based diet and hypothe-
more moderate in kidneys from mice fed a soy proteinsized that the soyasaponins may be associated with this thera-
peutic effect. The effects of feeding a saponin-enriched alcohol isolate (SPI), compared to animals fed a casein-based
extract (SEAE) from SPI, an isoflavone- and saponin-enriched diet [2]. This finding is consistent with reports of a bene-
soy supplement (Novasoy 400), or a 99.5% pure soyasaponin ficial therapeutic effect of soy-based diets on tissue mor-Bb powder on cyst growth are reported here.
phometry and the prolongation of renal function in hu-Methods. The therapeutic effects of the soyasaponins were
studied in 60-day-old male pcy mice in two separate, 90-day man kidney disease [3–6], as well as the extended survival
feeding trials. In the first study, mice were fed either a casein- and moderation of the pathologic changes in several
based (control) diet, a diet in which SPI replaced the casein animal models of kidney disease, including PKD [7–10].
or the control diet supplemented with SEAE. In the second
The component of SPI retarding cystogenesis and ex-study, mice were fed the control diet unsupplemented or sup-
tending tissue viability and extending functioning capac-plemented with either a soyasaponin- and isoflavone-enriched
soy product (Novasoy 400) or a 99.5% pure soyasaponin Bb ity in the pcy mouse kidney has not been identified. Iso-
powder. flavones, naturally present in SPI, have been suggested
Results. In study 1, kidney weight, water content, and plasma as the potentially active component(s) of SPI. Thesecreatinine and urea levels were markedly reduced in the SEAE-
reportedly function as tyrosine kinase inhibitors, reduc-fed animals compared to tissues from the control group; like-
ing the amount of activated growth factors available forwise, mice fed the SPI-based diet showed a decreased plasma
creatinine, but only a slightly reduced plasma urea. In study stimulating cyst growth in organ culture and curtailing
2, kidney weight, water content, plasma creatinine and urea further progression of cystic disease in a mouse model
levels were significantly reduced in mice fed the soyasaponin
of the autosomal-recessive form of PKD [11–14]. On theBb powder and the Novasoy-400 supplement, compared to
other hand, we have reported that supplementation of acontrols.
Conclusion. Soyasaponin Bb can impede kidney enlarge- casein-based diet with pure genistein in amounts several
ment and cyst growth in the pcy mouse model of PKD. Further times higher than those levels present in SPI had little
studies are needed to determine its most effective dose and effect on renal cyst development in the pcy mouse [2].mechanism of action.
SPI also contains saponins and it is possible that any
effect it has is associated with these high-molecular-
weight glycosides. Saponins are widely distributed in theOur studies in polycystic kidney disease (PKD) have
plant kingdom and consist of a diverse group of nonpolarconcentrated on various dietary interventions to attenu-
triterpene or steroid glycosides, linked to one or twoate cyst growth in the DBA/2 FG-pcy (pcy) mouse, an
polar oligosaccharides. Five forms of these amphiphilic
compounds (two forms belonging to the A and three to
1 ECORC contribution number, 991435. the B groups of soyasaponins) have been reported in
wild (Glycine soja) and cultivated (G. max) species ofKey words: saponin-enriched alcohol extract (SEAE), soyasaponin Bb,
cyst growth in PKD. soybean which may contain 0.2% to 0.8% of their dry
weight as soyasaponins, depending on plant strain, grow-Received for publication June 3, 2002
ing locale, and the amount carried over during the prepa-and in revised form October 24, 2002
Accepted for publication November 21, 2002 ration of the SPI [15–19]. Despite their relatively minute
amounts in foods, the soyasaponins are reported to have 2003 by the International Society of Nephrology
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significant effects on food intake [20], plasma cholesterol pended mixture was applied to the column and the col-
umn washed with three bed volumes of the respectivelevels [21, 22], epithelial cell proliferation [23], and cell
membrane permeability [24] in animals. resuspension solvent and the eluate concentrated in
vacuo. Under these conditions, the eluate contained allIn study 1, the effects of supplementing a casein-based
diet with a crude soyasaponin-enriched alcohol extract the saponins and isoflavones, while the more lipophilic
“fatty” components were absorbed by the column. The(SEAE) from SPI were compared to those changes found
in animals fed an unsupplemented casein-based diet, which resulting “defatted SPI fraction” was then reapplied to a
similar column of Octyl Sepharose CL-4B gel and elutedreportedly accelerates disease progression [2]. In study
2, the effects of supplementing a casein-based diet with with three bed volumes of acidified aqueous 25% EtOH
to give an isoflavone-enriched subfraction. Under thesepure soyasaponin Bb, the predominant soyasaponin found
in the SEAE, as well as the effects of supplementing the conditions, the soyasaponins were retained on the col-
umn and subsquently eluted using acidifed aqueous 80%casein-based diet with an isoflavone-enriched commer-
cial product (Novasoy 400; ADM, Decator, IL, USA) EtOH to give a soyasaponin-enriched subfraction.
Analyses of the soyasaponins in the SEAE utilizedcontaining this soyasaponin were examined.
both thin-layer chromatography (TLC) and high-perfor-
mance liquid chromatography (HPLC). For the TLC
METHODS
analyses, the soyasaponins were separated on MK C18:0
Preparation of a crude extract containing saponins reverse-phase plates (Whatman International, Ltd., Maid-
(SEAE) (study 1) stone, England) and visualized by spraying with 0.5%
p-anisaldehyde (vol/vol) in ethanol:concentrated sulfuricThe SEAE was extracted from the SPI (SuproPro
675 HG, Protein Technologies International, St. Louis, acid (95: vol/vol) followed by heating at 100C for 3 min-
utes (a characteristic rose-red color appears when soya-MO, USA) using a modified procedure of Kitagawa et al
[25]. Briefly, the SPI was stirred with methanol overnight saponins are present). The HPLC system consisted of a
Hypersil ODS column (250  4 mm, 5 m particle size)at room temperature followed by heating for 6 to 8 hours
and removal of the methanol in vacuo. coupled to a gradient delivery system (Thermo, Finni-
gan, Mississauga, Ontario, Canada) and an evaporativeThe resulting soy velasse was redissolved in a water:
n-butanol solvent system (1:1,v/v), and the phases al- light scattering detector (HPLC-ELSD; Varex MKIII,
Alltech Associates, Inc., Deerfield, IL, USA).lowed to separate. The butanol upper layer, containing
the saponins, was dried in vacuo. The residue was then Identification of the individual saponins in the SEAE
and SPI was done by comparative mass spectroscopyredissolved in a small amount of methanol and the sapo-
nins precipitated by the dropwise addition to a large using an authentic standard isolated and identified ac-
cording to Collins et al [26]. Mass spectroscopy ion flowvolume of ethyl acetate, followed by filtration and air
drying. The yield of the off-white powder containing the injection analyses (FIA) indicated the presence of a com-
pound with a molecular weight of 942, identical to ansaponins was 1.4% of the total weight of the SPI used.
authentic standard of soyasaponin Bb as reported by
Chemical characterization of the SEAE and SPI Shiraiwa, Harada, and Okubo [18], and as soyasaponin
I by Fuzzati et al [27]. Mass spectroscopic analyses ofAnalyses of the SPI isoflavone content were done us-
ing a modified procedure described by Collins et al [26]. the SEAE showed the presence of three small peaks
eluting at 12, 22, and 27 minutes into the run and aBriefly, the SPI was refluxed with acidified (0.1% acetic
acid, vol/vol) aqueous 80% ethanol (EtOH) during heat- much larger peak eluting at approximately 17 minutes.
Comparison of these analyses with published data al-ing; after cooling to room temperature, it was centrifuged,
the supernatant decanted, and the pellet re-extracted lowed identification of the first small peak, eluting at 12
minutes as soyasaponin Ba, the compound eluting at 22twice with additional acidified 80% EtOH. The com-
bined supernatants were then filtered and the filtrate minutes as soyasaponin Bc and the large peak eluting at
17 minutes as soyasaponin Bb. Quantitation of the totalevaporated in vacuo.
The SEAE and isoflavones recovered from the SPI saponins was expressed as microgram or milligram soya-
saponin Bb equivalents.were resuspended in either acidified (0.1% acetic acid)
aqueous 50% EtOH or 50% isopropyl alcohol, respec- Separation of the isoflavones in the SPI and SEAE
was done using the same column and solvent deliverytively, prior to their separation by hydrophobic interac-
tion chromatography on Octyl Sepharose CL-4B (Amer- system as that described for the soyasaponins, except that
the isoflavone compounds were detected by a Waters 991sham Pharmacia Biotech, Piscataway, NJ, USA). For
this step, a 30 mL bed volume gravity flow column of photo-diode array ultraviolet spectrophotometric detec-
tion system (Waters Corp., Milford, MA, USA). Identi-Octyl Sepharose CL-4B, pre-equilibrated in the appro-
priate solvent, was used to remove residual hydrophobic fication of the individual isoflavones was made by com-
parative chromatographic HPLC and ultraviolet spectralimpurities (i.e., “defatting”). Subsequently, the resus-
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analyses with published data [26, 27] and their amounts
expressed as microgram or milligram genistein equiva-
lents based on authentic standards (Sigma Chemical Co.,
St. Louis, MO, USA).
Purification of the soyasaponin Bb (study 2)
Novasoy 400 (ADM) and a prototypical “soy molas-
ses” fraction (Central Soya, Fort Wayne, IN, USA) were
used for the large scale purification of the approximately
5 g soyasaponin Bb needed for a feeding trial in the pcy
mice (study 2). The starting material from the ADM and
Central Soya products appeared as a yellowish-orange,
free-flowing powder, containing 5.3% soyasaponin Bb as
determined by HPLC-ELSD. The purification procedure
involved solubilization of the starting material (either the
Novasoy 400 or the soy molasses) in acidified aqueous
EtOH, followed by the group separation of the soyasap-
onin- and isoflavone-containing fractions by a scale up
of the analytical low-pressure liquid chromatography, Fig. 1. Structure of soyasaponin Bb (3-O-(-L-rhamnosyl-1→2--D-
galactosyl-1→2-D-glucuronosyl-olean-12-en-3,22, 24-triol) used todescribed in the previous section. The eluate from this
supplement the casein-based diet in study 2.step was concentrated in vacuo at 40C, redissolved in
aqueous alcohol (50% to 80% EtOH) and passed through
an anion exchange column, packed with QAE Sephadex
Feeding trials in the pcy mouseA-25 (Amersham Pharmacia Biotech) in the formate
form. The materials absorbed by the column, including Conditions for the housing and care of the pcy mice
the soyasaponin Bb, were recovered by washing the col- have been described previously [2]. All procedures were
umn with acidified aqueous 80% EtOH (containing 5% in accordance with the Canadian Council for Animal
formic acid). Further separation of soyasaponin Bb from Care Guidelines and were approved by the Animal Care
soyasaponins Ba and Bc was accomplished by preparative Committee at the University of Guelph.
hydrophobic interaction chromatography using a hexa- Sixty-day-old male pcy mice were randomly assigned
decyltrimethylammonium-substituted Sepharose Fast to treatment groups and fed ad libitum the diets shown
Flow Q gel (Amersham Pharmacia Biotech) prepared in Table 1. Body weight was measured weekly and the
and eluted according to Collins et al [26] with aqueous daily feed consumption over a 2-week period, midway
45% EtOH. The fraction containing the soyasaponin Bb in the trial, was recorded. After 90 days, the nonfasted
had a purity greater than 97% as determined by HPLC- mice were euthanized by exposure to CO2 as described
ELSD analyses. The residual coloration of this fraction by Tomobe et al [2]. The kidney and liver tissues were
and other impurities were removed by preparative liquid quickly removed and stored at80C until measurements
chromatography on Sephadex LH-20 (Amersham Phar- of tissue water content and cyst volume (quantitative
macia Biotech). HPLC analyses of this product showed morphometry) in study 1 and tissue water content in
a single, well-defined peak eluting 17 minutes into the study 2 could be made [9]. Organ water content was deter-
run. The soyasaponin was then recrystallized from hot mined by measuring the difference between tissue wet
aqueous EtOH to give colorless, tasteless, fine needle– weight and its weight after freeze-drying [2, 28]. Plasma,
shaped crystals used to supplement the casein-based diet. obtained by centrifugation of the heparinized cardiac
Co-chromatography (TLC-HPLC) and mass spectros- blood, was used for standard measurements of total pro-
copy confirmed that this material was 3-O-(-L-rhamno- tein, urea, and creatinine levels. Soy protein products
syl-1→2--D-galactosyl-1→2-D-glucuronosyl)-olean-12- enriched in soyasaponins are reportedly hypocholestero-
en-3,22, 24-triol (soyasaponin Bb). The structure of lemic in the hamster [29] and plasma cholesterol levels
the soyasaponin Bb is shown in Figure 1. were measured in studies 1 and 2 to determine if a similar
effect occurred in the pcy mouse. Comparisons were made
Characterization and quantitation of the soyasaponin between effects found in animals fed the casein-based
Authentic standards for the soyasaponins are not cur- (control) diet and the groups receiving the dietary treat-
rently available from commercial or private sources; ments using a one-way ANOVA (analysis of variance)
therefore, identification of the individual soyasaponins and the significance of these differences obtained by
was done using the previously described method of Col- the least significant difference (LSD) test [30]. The data
obtained in studies 1 and 2 were considered separately.lins et al [26].
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Table 1. Composition of the experimental diets
Diet ingredient Casein SPI  SEAE  Novasoy 400  Soyasaponin Bb
Casein, vitamin-free g/100 g diet 15.0 — 15.0 15.0 15.0
Soy protein isolate g/100 g diet — 15.0 — — —
Choline chloridea g/100 g diet 0.2 0.2 0.2 0.2 0.2
Vitamin/D L-methionine mixa g/100 g diet 1.0 1.0 1.0 1.0 1.0
Mineral mixa g/100 g diet 5.5 5.5 5.5 5.5 5.5
Cellulose g/100 g diet 2.45 2.45 1.95 0.5 2.27
Antioxidanta g/100 g diet 0.05 0.05 0.05 0.05 0.05
Corn oil g/100 g diet 15.0 15.0 15.0 15.0 15.0
Sucrose g/100 g diet 8.0 8.0 8.0 8.0 8.0
Cornstarch g/100 g diet 52.8 52.8 52.8 52.8 52.8
SEAE g/100 g diet — — 0.5 — —
Novasoy 400 g/100 g diet — — — 2.0 —
Soyasaponin Bb g/100 g diet — — — — 0.2
Abbreviations are: SPI, soy protein isolate; SEAE, saponin-enriched alcohol extract. Preparation of the SEAE is described in the Materials and Methods section.
a Antioxidants, vitamin and mineral mixes were added as previously described [2]
Three dietary treatments (Table 1) were used to assess Based on the soyasaponin Bb standard, the total soyasa-
the effect of the SEAE on cyst content in study 1. These ponin concentration in the SPI was estimated as 3.4 mg/g
included a control (casein-based) diet, a diet in which with soyasaponin Bb (3.0 mg/g) accounting for 88.1%
SPI replaced the casein, or the casein-based diet supple- of the total. Ireland, Dziedzic, and Kearsley [15] have
mented with the SEAE. In study 2, the mice were fed reported that the total soyasaponin content of SPI was
the unsupplemented control diet or this diet was supple- 7.6 mg/g, of which the group B soyasaponins represented
mented with either a soyasaponin- and isoflavone-enriched 72.5% or 5.5 mg/g SPI. Their estimate is slightly larger
soy product (Novasoy 400) or the 99.5% pure soyasa- than the amounts of the SPI soyasaponins found in the
ponin powder. The amount of soyasaponin Bb used to present experiment and may reflect the effects of grow-
supplement the casein-based diet was based on the soya- ing conditions or differences in the procedures used to
saponin Bb content of the SEAE used in study 1 (181 prepare the SPI. Small amounts of daidzin and genistin
mg/100 g diet rounded off to 0.1% of the diet). The (totaling2.5 mg/g) were also present in the SPI (Table 2).
Novasoy 400 contained 45.5 g isoflavones, 6.9 g total Soyasaponin Ba intake was similar in the SEAE and
saponins, and 5.3 g soyasaponin Bb/100 g material and SPI-fed groups (less than 0.1  0.0 mg/day), whereas
was added to the casein-based diet at 2% of the total intakes of the soyasaponins Bb and Bc in the SEAE-fed
diet (Fig. 2). All diets contained the same amounts of group were more than twice that amount consumed by
protein (150 g/kg) and had a similar physiologic fuel the SPI-fed mice. The average daily isoflavone intake
value (19.8 MJ/kg). for a 2-week period was estimated as 1.2  0.0 mg and
0.1  0 mg for the SPI- and SEAE-fed groups, respec-
tively (Table 2).
RESULTS
Chemical analyses of the SEAE and SPI supplements Effects of the SPI and SEAE-supplemented diets on
body and tissue weight, cyst volume, and kidney(study 1)
water contentQualitative TLC and HPLC analyses of the SEAE
showed that it contained four components giving a posi- Body weight was lowest in the SEAE-fed mice during
the first 9 weeks of the feeding trial (Fig. 3A); thereafter,tive color reaction as well as some early eluting peaks
representing the isoflavones (vide infra). As shown in it became similar among the three groups, as shown by
the values for final body weight in Table 3. The 2-weekTable 2, the total saponin content of this SEAE supple-
ment was 208.7 mg soyasaponin B/ g extract, the major feed intake did not differ among the control, SPI, and
SEAE groups (Table 3)portion of which was soyasaponin Bb (181.0 mg/g extract
or 86% of the saponin weight of the SEAE extract) with Feeding the SEAE supplement was associated with
the lowest kidney weight, compared to the casein-fedsmaller amounts of soyasaponins Ba and Bc. As well, the
SEAE contained small amounts (4.8 mg/g extract) of two (control) group; relative to body weight, kidney weights
from the SEAE-fed mice were75% those of the casein-isoflavone glycosides, daidzin and genistin.
TLC and HPLC-ELSD analyses of the SPI showed a fed animals. Total kidney weight, as grams/animal and
100 g body weight, did not differ between the casein andcomplex mixture of at least 11 compounds, of which
soyasaponin Bb, identified by co-chromatography with SPI-fed groups (Table 3). Liver weight (grams/animal)
was similar among the three groups; expressed as relativean authentic sample, was a major component (Table 2).
Fig. 2. High-performance liquid chromatography and evaporative light scattering detector (HPLC-ESLD) profile of Novasoy 400 [10L injection
of 25 mg/mL Novasoy 400 in 50% aqueous 80% ethanol (EtOH)]. As shown in the top trace, Novasoy 400 contains a fairly large proportion
of isoflavone glycoside derivatives and small amounts of the corresponding aglycones eluting during the first 12 minutes of the run; the soyasaponins
eluted during 30 to 32 minutes of the run. The elution pattern for the individual soyasaponins is shown in a magnification of the saponin zone
(encircled insert) and shows that soyasaponin Bb is the major soyasaponin present, followed by lesser amounts of soyasaponin Bc and Ba, and two
unidentified saponins. Quantitation was carried out using a standard curve of soyasaponin Bb and an integration curve based on the quadratic
equation y 	 1.109x2  12.38x (R2 	 0.996) where y is expressed in mv · sec-1 · 105 and x is expressed in mg/mL soyasaponin Bb equivalents.
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Table 2. Soyasaponin and isoflavone concentrations of the soy protein isolate (SPI) and saponin-enriched alcohol extract (SEAE) (study 1)
and total soyasaponin, soyasaponin Bb, and isoflavone intakes by pcy mice fed either Novasoy 400 or soyasaponin Bb (study 2)
Study 1 SPI SEAE
Total soyasaponins mg/g material 3.4 208.7
Soyasaponin Ba 0.1 1.5
Soyasaponin Bb 3.0 181.0
Soyasaponin Bc 0.4 24.0
Unknown saponin(s) None detected 2.1




Soyasaponin Bb 1.40.4 2.80.1
Soyasaponin Bc 0.20.0 0.40.0
Unknown saponin(s) None detected 0.30




Total isoflavone intake mg/day 1.20.0 0.10.0
Study 2 Novasoy 400 (9)a Soyasaponin Bb (9)a
Total soyasaponin intake mg/day 5.30.2 5.90.4
Soyasaponin Bb intake mg/day 4.10.1 5.90.4
Total isoflavone intake mg/day 35.12.6 —
aNumbers in parentheses show number of animals/group
to body weight, weight of this tissue was lower in the the first week of the trial and remained the lowest among
the three groups during the remainder of the feedingSPI- and SEAE-fed groups than in the casein-fed group
(Table 3). trial (Fig. 3B). Feed intake did not did not differ among
the groups (Table 5). The estimated total soyasaponinMorphometric analyses showed a significantly lower
mean cyst volume in the right kidneys from the SEAE- intake in the Novasoy 400–fed mice was 5.3  0.2 mg/
day, of which 4.1  0.1 mg was soyasaponin Bb; micesupplemented group, as compared to tissues from the
casein-fed (control) group (Table 3). Cyst volume was fed this diet also consumed approximately 35.1 2.6 mg
isoflavone/day as daidzin and genistin. The amount ofalso lower in the SPI-fed mice, although this difference
did not achieve statistical significance (Table 3) Values soyasaponin Bb consumed by the mice fed the pure soya-
saponin was slightly higher than the amount eaten byfor the kidney water content (as grams/left kidney) mir-
rored these changes in cyst volume, but there was no the Novasoy 400–supplemented group (5.9 0.0 versus
4.1  0.1 mg/day, respectively).difference among the groups when water content was
expressed as %. This similar % water content among Supplementation with Novasoy 400 and soyasaponin
Bb was associated with significantly lower kidney weightthe three groups suggests that the reduced cyst volume
found in the SEAE- and SPI-fed groups could not be (as g/animal and g/100 g body weight) compared to the
casein-fed control group. Absolute liver weight did notattributed to changes in cyst proportion The water con-
tent of the liver was similar among the unsupplemented differ among the three groups (Table 5); however, liver
weight, expressed relative to body size, was highest inand supplemented groups (Table 3).
Plasma creatinine and urea contents were lowest in the Novasoy 400-fed mice, consistent with the lower
body weight of this group. Also, kidney water contentthe SEAE-supplemented group (51% and 63% of the
amounts found in the casein-fed control group, respec- as g/left kidney was decreased in the Novasoy 400 and
soyasaponin Bb-fed mice, compared to the control group,tively). These values were also decreased in the SPI-fed
mice compared to the control group, although none of although there were no significant differences among
these groups when the water content was expressed asthese reductions in plasma urea achieved statistical sig-
nificance. Plasma total protein and cholesterol level did a percent (Table 5). Likewise, liver water given as a
percent did not differ among these groups (Table 5).not differ among the three groups (Table 4).
Plasma creatinine and urea levels were lower in the
Effects of the Novasoy 400 and the soyasaponin Bb Novasoy 400 and the soyasaponin Bb–supplemented
on body and tissue weight and composition groups, compared to those levels found in mice fed the
casein-based (control) diet (Table 6). Plasma cholesterolBody weight was similar in the control and soyasa-
ponin Bb-supplemented groups throughout the feeding level in animals fed the Novasoy 400 was lower than
that of the casein-fed group but not the soyasaponintrial; however, mice fed the Novasoy 400–based diet
showed a decrease from the initial body weight during Bb–supplemented group. This difference between the
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Table 3. Body and tissue weight, cyst volume, and kidney water
content in pcy mice fed either the casein or soy protein isolate
(SPI)-based diets and the casein-based diet  saponin-enriched
alcohol extract (SEAE) (study 1)
Diet measurement Casein (8) SPI (7) SEAE (6)
Final body weight g 27.01.2a 27.81.1 26.00.7
Two-week food intake
g/day 3.20.1 3.10.1 3.20.2
Total kidney weight
g/animal 1.60.1 1.50.1 1.20.1b
Range g (1.4–2.1) (1.1–2.0) (1.0–1.4)
Total kidney weight
g/100 g body weight 5.80.4 5.60.4 4.50.3c
Liver weight g/animal 1.20.2 1.10.1 1.00.1
Liver weight
g/100 g body weight 4.30.1 4.00.1b 4.00.1b
Cyst volume
mL/right kidney 0.680.05 0.570.07 0.410.05b
Kidney water content
g/left kidney 0.730.05 0.620.05 0.550.03b
Kidney water content % 89.61.6 85.52.3 88.41.0
aValues are given as meanSEM for the number of animals shown in the
parentheses; bP 
 0.01; cP 
 0.001, significantly different from the casein-fed
animals.
Table 4. Plasma chemisteries in pcy mice fed either the casein- or
soy protein isolate (SPI)-based diet or the casein-based diet 
saponin-enriched alcohol extract (SEAE) (study 1)
Diet measurement Casein (8) SPI (7) SEAE (6)
Plasma creatinine lmol/L 35.36.0a 21.55.5c 18.06.0d
Plasma urea mmol/L 10.21.4 7.92.7 6.41.2b
Plasma cholesterol mmol/L 3.50.4 4.60.3 3.30.2
Plasma total protein g/L 40.23.6 46.41.4 41.72.5
aData are given as meanSEM for the number of mice shown in the paren-
Fig. 3. Average weights. (A ) Average body weight of pcy mice fed a theses
casein-based diet (), the soy protein isolate (SPI)-based diet (), or bP 
 0.05; cP 
 0.01; dP
 0.001, significantly different from the control group
the casein-based diet supplemented with soyasaponin-enriched alcohol
extract (SEAE) () (study 1). (B ) Average body weight of pcy mice
fed the casein-based diet unsupplemented (), this diet supplemented
with Novasoy 400 (), or supplemented with soyasaponin Bb ()
(study 2). Table 5. Body and tissue weight and water and dry matter contents
in pcy mice fed the casein-based diet or this diet supplemented
with either Novasoy 400 or soyasaponin Bb (study 2)
Casein Novasoy 400 Soyasaponin BbNovasoy 400 and the soyasaponin Bb–fed mice suggests Diet measurement (9) (9) (9)
that soyasaponin Bb on its own may not hypocholestero- Final body weight g 25.20.9a 23.30.8c 25.10.1
lemic or that it may require factors, such as other soyasa- Two-week food
intake g/day 3.40.9 3.90.9 3.30.5ponins and the isoflavones, for this property. Total
Total kidney weightplasma protein levels did not differ among the three
g/animal 1.80.1 1.30.1c 1.30.1c
dietary groups. Total kidney weight
g/100 g body weight 7.00.3 5.40.3c 5.20.3d
Liver weight g/animal 1.20.1 1.30.1 1.20
Liver weightDISCUSSION
g/100 g body weight 4.60.1 5.60.4c 4.60.1
We have reported that kidney size was reduced in pcy Liver water % 69.60.5 70.50.4 69.40.4
Kidney water contentmice fed diets supplemented with an extract (SEAE)
g/left kidney 0.820.03 0.630.07b 0.610.04dcontaining soyasaponins, an isoflavone-enriched extract
Kidney water content % 89.00.5 88.10.8 88.20.5
(Novasoy 400) as well as pure soyasaponin Bb. Total Kidney dry matter
mg/left kidney 87.24.5 81.86.5 82.34.2kidney weight of mice fed the SEAE, Novasoy 400, and
a Values are given as meanSEM for the number of animals shown in paren-soyasaponin Bb–supplemented diet was approximately
theses23% to 27% lower than observed in pcy mice fed a bP
 0.05; cP
 0.01; dP
 0.001, significantly different from the corresponding
casein-fed groupcasein-based diet. The kidney to body weight ratio
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Table 6. Plasma chemisteries in pcy mice fed a casein-based diet or this diet supplemented with either Novasoy 400
or soyasaponin Bb (study 2)
Diet measurement Casein (9) Casein  Novasoy 400 (9) Casein  soyasaponin Bb (9)
Plasma creatinine lmol/L 26.02.8a 19.02.5b 17.51.8c
Plasma urea mmol/L 3.70.4 2.10.3c 2.80.2b
Plasma cholesterol mmol/L 5.30.2 4.30.2c 4.80.3
Plasma total protein g/L 56.01.9 56.00.8 54.31.1
aValues are meanSEM for number of animals in parentheses
bP 
 0.05; cP 
 0.01, significantly different from the corresponding casein-fed group
showed the same progression, suggesting that the de- rats fed diets in which soy protein replaced the casein
as the protein source [10, 33]. Elevated plasma creatininecreased kidney weight in the SEAE, Novasoy 400, and
soyasaponin Bb-supplemented groups did not depend levels have been reported in other animal models of
PKD and associated with enhanced cyst developmenton other, nonspecific changes in growth. Our findings
indicate that cyst development in the pcy mouse kidney and the onset of proteinuria and/or azotemia, indicative
of a compromised renal function [34, 36, 37]. In thecould be attenuated by feeding soyasaponin- enriched
soy products such as SEAE or soyasaponin Bb; these present study, changes in plasma urea contents were less
remarkable than those observed for the plasma creati-products are nearly isoflavone-free, suggesting that the
isoflavones play a relatively minor role in the suppression nine levels and ranged from 29%, 38%, and 24% reduc-
tions in the SPI-, SEAE-, and soyasaponin Bb/Novasoyof cyst growth.
Studies in other animal models of PKD, including the 400–fed groups, respectively. Significant reductions in
the creatinine and urea levels have been observed inHan:SPRD rat [32, 33] the CD-1 pcy/pcy mouse [10],
the kat/kat2 J mouse [34], and the BDF-1-pcy hybrid mouse and rat models of PKD fed soy protein–based
diets [2, 9], as well as during a moderate protein restric-mouse [35], have shown that increased organ and cyst
size and water content are associated with age and in- tion [38]. Urea is reportedly toxic to the kidney in a
number of species [39, 40] and reduced serum levelscreasing severity of the disease. Morphometric measure-
ments of cyst volume in the right kidney from the casein- of this end product of protein metabolism have been
associated with preservation of renal function and atten-fed, SPI-fed, and the SEAE-supplemented groups in
study 1 indicated that cyst development was least in the uation of those inflammatory reactions found in the in-
terstitium of the cystic kidney [9, 35].SEAE-supplemented group, increased slightly, although
not significantly, in the SPI-fed group, and was greatest The mechanism by which soyasaponin Bb controls cyst
growth in the pcy mouse kidney has not been elucidated.in the casein-fed mice. This reduction in kidney weight
was associated with a reduced water content in the soy Ex vitro studies in bovine aortic and tracheal smooth
muscle cells have shown that the group B soyasaponinsprotein–fed groups, as compared to the casein-fed ani-
mals (Table 3). Cyst volume measurements were not made and the structurally similar analog, dehydrosoyasaponin
I (DHS-I), can extend the open probability time of thein the Novasoy 400– and soyasaponin Bb–supplemented
groups in study 2, although the kidney water content high conductance, outwardly rectifiying potassium chan-
nels (or maxi-K channels) [41, 42]. This response towas markedly reduced in these groups compared to the
casein-fed mice (Table 5). These findings support our DHS-I and the soyasaponins B is apparently unique to
these channels, found throughout the nephron whereprevious observation that the cyst fluid in the pcy mouse
kidney is mainly water and gives further support to the they may act as cell volume regulators [43, 44]. It is
possible that increasing the open probability of thesesuggestion that kidney water content is a good indicator
of cyst development [28, 31]. Dry kidney weight was maxi-K channels serves to limit the amount of potas-
sium accumulated within the cell/cyst cytoplasm andsimilar in all groups, indicating that the aqueous compo-
nent of this tissue did not change, as reported in the further solute secretion into the cell and/or cyst sac.
Alternatively, the soyasaponins may destabilize mem-kat/kat2 J [34] and in the C57BL/6J-cpk mouse [28].
Plasma creatinine and urea levels were reduced in brane structure and disrupt permeability in a manner
similar to that described for the cauloside C saponins [24].the Novasoy 400, soyasaponin Bb, SPI, and SEAE-fed
groups, compared to the casein-fed group (Tables 4 and This response of the pcy mouse kidney to the group
B soyasaponins may be highly specific. In a previous6). For plasma creatinine, these reductions ranged from
27% in the Novasoy 400–fed group to 33%, 39%, and study (unpublished), we found that supplementation of
the casein-based diet with ginseng (Panax notoginseng)49% found in the soyasaponin Bb-, SPI-, and the SEAE-
fed groups, respectively. Decreased plasma creatinine root containing saponins [45] had no effect on kidney
size and cyst development when fed at the level of 5%levels have been reported in pcy mice and in Han:SPRD
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4. D’Amico G, Gentile MG: Influence of diet on lipid abnormalitiesof the diet. This finding suggests that, unlike the soyasa-
in human renal disease. Am J Kidney Dis 22:151–157, 1993
ponins, the ginseng-derived saponins may have little ef- 5. Gentile MG, Fellin G, Cofano F, et al: Treatment of proteinuric
fect on cyst development in the pcy mouse model of PKD. patients with a vegetarian soy diet and fish oil. Clin Nephrol 40:315–
320, 1993
6. Soroka N, Silverberg DS, Greemland M, et al: Comparison of
a vegetable-based (soya) and an animal-based low-protein diet inCONCLUSION
predialysis chronic renal failure patients. Nephron 79:173–180, 1998
7. Williams AJ, Baker F, Walls J: Effect of varying quantity andOur studies have shown a 25% reduction in kidney
quality of dietary protein intake in experimental renal disease insize and water content when a SEAE was used to supple-
rats. Nephron 46:83–90, 1987
ment a casein-based diet (study 1) and reductions of 8. Howie AJ, Kizaki T, Beaman M, et al: Different types of segmental
sclerosing glomerular lesions in six experimental models of protein-23% and 26% when this casein-based diet was supple-
uria. J Pathol 157:141–151, 1989mented with either Novasoy 400 or soyasaponin Bb, 9. Ogborn MR, Bankovic-Calic N, Shoesmith C, et al: Soy protein
respectively. Replacement of the casein protein with SPI modification of rat polycystic kidney disease. Am J Physiol 274
(Renal Physiol) 43:F541–F549, 1998in study 1 was associated also with a slight decrease in
10. Aukema HM, Housini I, Rawling J: Dietary soy protein effectskidney size that was smaller than that reported for the
on inherited polycystic kidney disease are influenced by gender
SPI-fed mice in our previous paper [2]. These results and protein level. J Am Soc Nephrol 10:300–308, 1999
11. Linassier C, Pierre M, LePecq JB, et al: Mechanism of action inshow that a reduced kidney size is a consistent finding
N1H 3T3 cells of genisten: an inhibitor of the EGF repector tyro-in the SPI-fed mouse, although the extent of this change
sine kinase activity. Biochem Pharmacol 39:187–193, 1989
may be very variable. 12. Pugh JL, Sweeney WE, Avner ED: Tyrosine kinase activity of
the EGF receptor in murine metanephritic organ culture. KidneyRecently, attenuations of lesion incidence and severity
Int 47:774–781, 1995were reported in kidneys from Imai hypertensive rats
13. Richards WG, Sweeney WE, Yoder BK, et al: Epidermal growth
fed a semipurified alcohol extract of soy protein and factor receptor activity mediates renal cyst formation in polycystic
kidney disease. J Clin Invest 101:935–939, 1998enriched in the total soyasaponins [46]. These results
14. Sweeney WE Jr, Chen Y, Nakanishi K, et al: Treatment of polycys-confirm previous reports that cyst growth in PKD can
tic kidney disease with a novel tyrosine kinase inhibitor. Kidney
be moderated by dietary means [2, 9, 10] and point to Int 37:33–40, 2000
the therapeutic effectiveness of soybean. Results from 15. Ireland PA, Dziedzic SZ, Kearsley MW: Saponin content of soya
and some commercial soya products by means of high-performancethe present study show that soyasaponin Bb, present in
liquid chromatography of the sapogenins. J Sci Food Agri 37:694–
minute amounts in soy-derived products, may be an ef- 698, 1986
fective therapeutic agent for attenuation of cyst growth 16. Price KR, Eagles J, Fenwick GR: Saponin composition of 13
varieties of legume seed using fast atom bombardment mass spec-in the pcy mouse model of PKD. Future studies will
trometry. J Sci Food Agri 42:183–193, 1988determine the most effective therapeutic dose, the effects 17. Taniyama T, Yoshikawa M, Kitagawa I: Saponin and Sapogenol.
of gender and age at initiation of therapy for the maximal XLIV. Soyasaponin composition in soybeans of various origins
and soyasaponin content in various organs of soybean. Structureefficacy of this treatment.
of soyasaponin V from soybean hypocotyl. Yakugaku Zasshi
108:562–571, 1988
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